CD8A and glioblastoma: In vivo evaluations revealed that intracavitary implantation of the HA-DOX-containing paste significantly prolonged the median survival of treated mice compared to the untreated group (37 days vs 25 days, respectively) and modulated the glioblastoma-associated TIME, resulting in a 44% reduction in GSC levels and a significant increase in CD8<sup>+</sup> T cell levels (∗p < 0.5), compared to resected mice.